세계의 재조합 단백질 제조 서비스 시장 : 시장 규모 조사 - 서비스 유형별, 숙주 세포별, 최종 사용자별, 지역별 예측(2022-2032년)

Global Recombinant Proteins Manufacturing Services Market is valued approximately at USD 4.52 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 17.79% over the forecast period 2024-2032. Recombinant proteins manufacturing services involve the production of proteins by inserting desired genes into host cells like bacteria, yeast, or mammalian cells. These services are vital for applications in biotechnology, pharmaceuticals, and research, providing tailored solutions for gene synthesis, cloning, expression, purification, and quality control. With the increasing need for high-yield and high-purity protein production, these services cater to the specific demands of scientific and medical industries.

Recombinant proteins play a critical role in developing innovative therapeutics for chronic conditions, including cancer and rare disorders. The production of recombinant pharmaceutical proteins in heterologous systems has seen rising demand. Furthermore, the ongoing advancements in recombinant technology are expanding the applications of proteins in personalized medicine, cell and gene therapies, and bioengineering products. For example, gene editing technologies like CRISPR-Cas9 have enabled precise alterations in recombinant proteins, fostering the creation of novel therapeutics.

The biopharmaceutical industry's remarkable growth drives the increasing demand for recombinant proteins manufacturing services. The industry's rapid expansion is fueled by factors like the rising prevalence of complex diseases, a shift towards personalized medicine, and the development of innovative targeted therapies. The biopharmaceutical sector heavily relies on recombinant proteins for research, drug development, and therapeutic production, especially in the production of biologics such as monoclonal antibodies, therapeutic proteins, and vaccines. This reliance ensures a consistent demand for recombinant proteins manufacturing services.

The rise of personalized medicine and targeted therapies has also significantly boosted the demand for recombinant proteins manufacturing services. Personalized medicine focuses on tailoring medical treatments to an individual's genetic, molecular, and clinical characteristics, requiring highly specific and effective therapeutic solutions. Recombinant proteins are pivotal in developing these therapies, offering an adaptable and customizable platform for creating biologics that align precisely with a patient's genetic and molecular profile.

The increasing prevalence of chronic diseases worldwide is another major driver for the recombinant proteins manufacturing services market. Chronic diseases like cancer, diabetes, cardiovascular disorders, and autoimmune conditions necessitate the development of novel treatments and diagnostic tools. Recombinant proteins are indispensable for understanding the molecular basis of these conditions and developing targeted therapies and diagnostic tests. As chronic diseases continue to rise, the demand for recombinant proteins manufacturing services grows, supporting the research, clinical trials, and diagnostic applications needed to combat these health challenges.

In terms of regional dominance, North America held the largest market share in 2023. The region's substantial demand for biologic therapies, robust research and development ecosystem, and high prevalence of chronic diseases contribute to this dominance. North America's well-established healthcare infrastructure and the presence of prestigious academic institutions and research-driven companies further drive the demand for recombinant proteins manufacturing services. Meanwhile, the Asia Pacific market is expected to experience significant growth during the forecast period, driven by increasing government initiatives, rising healthcare investments, and a growing pediatric population.

Major market players included in this report are:

• Lonza
• Boehringer Ingelheim International GmbH
• FUJIFILM Diosynth Biotechnologies
• Merck KGaA
• Bruker (InVivo BioTech Services GmbH)
• Sino Biological, Inc.
• GenScript
• Kaneka Corporation (Kaneka Eurogentec S.A)
• Polyplus Transfection (Xpress Biologics)
• Boster Biological Technology
• Trenzyme GmbH

The detailed segments and sub-segment of the market are explained below:

By Service Type:

• Pre-clinical & Clinical Services
• Commercial Production Services

By Host Cell:

• Mammalian Cells
• Bacterial Cells
• Insect Cells
• Yeast & Fungi
• Others

By End-user:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Recombinant Proteins Manufacturing Services Market Executive Summary

• 1.1. Global Recombinant Proteins Manufacturing Services Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Service Type
  • 1.3.2. By Host Cell
  • 1.3.3. By End-user
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Recombinant Proteins Manufacturing Services Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Recombinant Proteins Manufacturing Services Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Expansion of the Biopharmaceutical Industry
  • 3.1.2. Personalized Medicine and Targeted Therapies
  • 3.1.3. Rising Prevalence of Chronic Diseases
• 3.2. Market Challenges
  • 3.2.1. High Costs and Complex Manufacturing Processes
  • 3.2.2. Regulatory and Quality Compliance
• 3.3. Market Opportunities
  • 3.3.1. Advancements in Recombinant Technology
  • 3.3.2. Growing Demand in Emerging Markets
  • 3.3.3. Innovations in Gene Editing Technologies

Chapter 4. Global Recombinant Proteins Manufacturing Services Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Recombinant Proteins Manufacturing Services Market Size & Forecasts by Service Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Recombinant Proteins Manufacturing Services Market: Service Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Pre-clinical & Clinical Services
  • 5.2.2. Commercial Production Services

Chapter 6. Global Recombinant Proteins Manufacturing Services Market Size & Forecasts by Host Cell 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Recombinant Proteins Manufacturing Services Market: Host Cell Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Mammalian Cells
  • 6.2.2. Bacterial Cells
  • 6.2.3. Insect Cells
  • 6.2.4. Yeast & Fungi
  • 6.2.5. Others

Chapter 7. Global Recombinant Proteins Manufacturing Services Market Size & Forecasts by End-user 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Recombinant Proteins Manufacturing Services Market: End-user Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Pharmaceutical & Biotechnology Companies
  • 7.2.2. Academic & Research Institutes

Chapter 8. Global Recombinant Proteins Manufacturing Services Market Size & Forecasts by Region 2022-2032

• 8.1. North America Recombinant Proteins Manufacturing Services Market
  • 8.1.1. U.S. Recombinant Proteins Manufacturing Services Market
    • 8.1.1.1. Service Type breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Host Cell breakdown size & forecasts, 2022-2032
    • 8.1.1.3. End-user breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Recombinant Proteins Manufacturing Services Market
• 8.2. Europe Recombinant Proteins Manufacturing Services Market
  • 8.2.1. U.K. Recombinant Proteins Manufacturing Services Market
  • 8.2.2. Germany Recombinant Proteins Manufacturing Services Market
  • 8.2.3. France Recombinant Proteins Manufacturing Services Market
  • 8.2.4. Spain Recombinant Proteins Manufacturing Services Market
  • 8.2.5. Italy Recombinant Proteins Manufacturing Services Market
  • 8.2.6. Rest of Europe Recombinant Proteins Manufacturing Services Market
• 8.3. Asia-Pacific Recombinant Proteins Manufacturing Services Market
  • 8.3.1. China Recombinant Proteins Manufacturing Services Market
  • 8.3.2. India Recombinant Proteins Manufacturing Services Market
  • 8.3.3. Japan Recombinant Proteins Manufacturing Services Market
  • 8.3.4. Australia Recombinant Proteins Manufacturing Services Market
  • 8.3.5. South Korea Recombinant Proteins Manufacturing Services Market
  • 8.3.6. Rest of Asia Pacific Recombinant Proteins Manufacturing Services Market
• 8.4. Latin America Recombinant Proteins Manufacturing Services Market
  • 8.4.1. Brazil Recombinant Proteins Manufacturing Services Market
  • 8.4.2. Mexico Recombinant Proteins Manufacturing Services Market
  • 8.4.3. Rest of Latin America Recombinant Proteins Manufacturing Services Market
• 8.5. Middle East & Africa Recombinant Proteins Manufacturing Services Market
  • 8.5.1. Saudi Arabia Recombinant Proteins Manufacturing Services Market
  • 8.5.2. South Africa Recombinant Proteins Manufacturing Services Market
  • 8.5.3. Rest of Middle East & Africa Recombinant Proteins Manufacturing Services Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Lonza
  • 9.1.2. Boehringer Ingelheim International GmbH
  • 9.1.3. FUJIFILM Diosynth Biotechnologies
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Lonza
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Boehringer Ingelheim International GmbH
  • 9.3.3. FUJIFILM Diosynth Biotechnologies
  • 9.3.4. Merck KGaA
  • 9.3.5. Bruker (InVivo BioTech Services GmbH)
  • 9.3.6. Sino Biological, Inc.
  • 9.3.7. GenScript
  • 9.3.8. Kaneka Corporation (Kaneka Eurogentec S.A)
  • 9.3.9. Polyplus Transfection (Xpress Biologics)
  • 9.3.10. Boster Biological Technology

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes